Business
Janux Therapeutics to Present Preclinical Data at the 18th Annual PEGS Boston for PSMA-TRACTr and EGFR-TRACTr
-PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) exhibit enhanced safety and PK properties relative to unmasked TCE- -Enhanced PK profile and high exposure
About this update from Janux Therapeutics, Inc.
[{"type":"text","content":"\n-PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008) exhibit enhanced safety and PK properties relative to unmasked TCE-\n\n-Enhanced PK profile and high exposure of TRACTrs were well tolerated in NHP safety studies with limited healthy tissue toxicities and cytokine release syndrome-\n\n-Data highlight potential of Janux’s TRACTr technology platform to support clinical development-\n\n-Company remains on-track to submit IND filings for JANX007 in 1H 2022 and JANX008 in 2H 2022-\n\n SAN DIEGO--(BUSINESS WIRE)--\nJanux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced its upcoming presentation of preclinical data for the Company’s two lead TRACTr programs, PSMA-TRACTr (JANX007) and EGFR-TRACTr (JANX008), in separate poster presentations at the 18th Annual Protein & Antibody Engineering Summit (PEGS) Boston Conference & Expo, scheduled to take place May 2-6, 2022, virtually and in-person at the Hynes Convention Center in Boston, Massachusetts.\n\nJanux’s TRACTr candidates are a novel class of T cell engagers (TCEs) designed to be highly potent, half-life extended anti-tumor therapeutics with enhanced safety features and the potential to overcome problems with existing TCE approaches for solid tumors, which have been limited to date by cytokine release syndrome (CRS), on-target healthy tissue toxicity, poor pharmacokinetics (PK) profiles, and dose-limited efficacy. JANX007 is a novel TRACTr therapeutic targeting prostate-specific membrane antigen (PSMA) for the treatment of metastatic castration-resistant prostate cancer (mCPRC), and JANX008 is a novel TRACTr therapeutic targeting epidermal growth factor receptor (EGFR) for the treatment of multiple solid cancers including, metastatic colorectal cancer (mCRC), squamous cell carcinoma of the head and neck (SCCHN), and non-small cell lung cancer (NSCLC). JANX007 and JANX008 are the first development programs to emerge from Janux’s TRACTr platform.\n\n“The preclinical data to be presented for JANX007 and JANX008 at PEGS Boston is an important step forward for Janux’s proprietary TRACTr technology platform and our pipeline of next-generation immunotherapies,” ...